[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

16 clusters · 450 sources · 51 days · First seen · Last updated

Moderna and Merck melanoma vaccine clinical trials

Overview

Moderna and Merck (MSD) have reported positive Phase 3 clinical trial results for intismeran autogene (V940), an experimental personalized mRNA cancer vaccine. The INTerpath-001 trial, which administered the vaccine alongside Merck’s Keytruda, met its primary endpoint of recurrence-free survival, reducing the risk of recurrence or death by 49% compared to Keytruda monotherapy. Moderna President Stephen Hoge stated the study demonstrated a “statistically significant and clinically meaningful benefit over Merck’s KEYTRUDA.”

Following these results, Moderna shares experienced significant volatility. While clinical success initially triggered a 177% surge, the stock later rose 12.27% to close at $172.94 on September 21, 2026, after three abstracts regarding the data were accepted for the 2026 ESMO Congress.

However, Moderna faces headwinds. Citigroup downgraded the stock from ‘Neutral’ to ‘Sell’, with analyst Geoff Meacham suggesting the current valuation is overly optimistic. Additionally, a federal court in Delaware denied Moderna's request to dismiss a patent lawsuit involving mRNA technology. In a separate development, Moderna is set to join the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery.

As the company prepares for potential commercialization of V940, it is deepening collaborations with Merck and Tempus. Under an expanded agreement, Tempus will manage tumor tissue and blood sample collection and provide sequencing services, marking a transition from clinical trials toward industrial implementation. Investor confidence has also been bolstered by reports of a planned national public-private partnership, potentially involving the National Institutes of Health, aimed at accelerating cancer vaccine development starting in December.

Entities

Moderna · Merck · Merck & Co. · Moderna Inc. · Nasdaq

Claims

What the coverage asserts, and how many sources carry each claim.

Coverage disagrees

Sources make claims that cannot both be true. CLSTR reports the disagreement; it does not decide who is right.

Timeline

  1. [BUSINESS] 2 sources
    Moderna expands cancer therapy ties and benefits from vaccine program news

    Moderna shares rose following news of an expanded cancer therapy alliance with Merck and Tempus, alongside reports of a new national program to accelerate mRNA cancer vaccine development.

  2. [BUSINESS] 2 sources
    Moderna to join Nasdaq-100 replacing Warner Bros. Discovery

    Moderna will join the Nasdaq-100 on October 9, replacing Warner Bros. Discovery following a massive surge in share price driven by its cancer vaccine developments.

  3. [BUSINESS] 7 sources
    Moderna shares fall after Citigroup downgrade

    Moderna shares fell after Citigroup downgraded the stock to ‘Sell’, citing concerns that the company's valuation requires unrealistic oncology sales to justify recent gains driven by cancer vaccine optimism.

  4. [BUSINESS] 2 sources
    Moderna stock surges over 24% in a single week

    Moderna stock surged over 24% this week, breaking through key multi-year resistance levels to approach $200 per share amid a broader market rotation into biotech.

  5. [BUSINESS] 5 sources
    Moderna to present Phase 3 melanoma vaccine data at ESMO Congress

    Moderna will present Phase 3 data for its personalized melanoma vaccine, Intismeran Autogene, at the ESMO Congress on October 24, marking a strategic expansion into oncology via its mRNA platform.

  6. [BUSINESS] 3 sources
    Moderna pivots mRNA strategy toward oncology amid rising biotech competition

    Moderna is pivoting its mRNA technology toward oncology following successful clinical trials, amid a global rise in mRNA cancer vaccine research led by Chinese biotech innovation.

  7. [BUSINESS] 7 sources
    Moderna shares surge on cancer vaccine clinical data news

    Moderna shares surged following the announcement that its mRNA cancer vaccine, intismeran autogene, will be featured at the ESMO Congress, highlighting the company's expansion into oncology.

  8. [BUSINESS] 3 sources
    Moderna reports positive Phase III results for personalized cancer vaccine

    Moderna reported positive Phase III results for its personalized cancer vaccine, intismeran, in melanoma treatment, prompting both clinical optimism and market valuation concerns.

  9. [BUSINESS] 4 sources
    Moderna stock surges following successful melanoma vaccine trials

    Moderna's stock has surged over 500% in the past year, driven by updated COVID-19 vaccine approvals and successful Phase 3 clinical trials for an mRNA-based melanoma treatment developed with Merck.

  10. [BUSINESS] 4 sources
    Moderna issues 3 billion US dollars in convertible notes

    Moderna shares rose nearly 10% following the announcement of a 3 billion US dollar zero-interest convertible note placement to fund oncology research and debt reduction.

  11. [HEALTH] 13 sources
    Moderna and Merck report successful Phase 3 mRNA cancer vaccine trial

    Moderna and Merck's Phase 3 INTerpath-001 trial showed that a personalized mRNA cancer vaccine combined with Keytruda significantly reduces melanoma recurrence and death risks.

  12. [HEALTH] 2 sources
    Medical breakthrough improves survival rates for advanced melanoma

    A combination of pembrolizumab immunotherapy and mRNA-based intismerán has shown significant success in increasing survival rates and preventing recurrence in advanced malignant melanoma patients.

  13. [BUSINESS] 6 sources
    Moderna expands convertible bond offering to up to $3 billion

    Moderna is raising up to $3 billion through convertible notes to fund its oncology pipeline and repay debt, following positive clinical trial results for its melanoma vaccine developed with Merck.

  14. [HEALTH] 38 sources
    Moderna and Merck announce successful Phase 3 mRNA melanoma vaccine trial

    Moderna and Merck reported successful Phase 3 trial results for a personalized mRNA melanoma vaccine, which significantly reduces recurrence risk when combined with Keytruda.

  15. [HEALTH] 2 sources
    Málaga hospital leads trial for personalized mRNA melanoma vaccine

    A phase 3 clinical trial for a personalized mRNA melanoma vaccine has shown positive results in reducing relapse and metastasis risks, with significant participation from Málaga's Hospital Regional.

  16. [HEALTH] 399 sources
    Moderna and Merck report positive Phase 3 results for mRNA melanoma vaccine

    Moderna and Merck reported positive Phase 3 trial results for a personalized mRNA melanoma vaccine, which met primary endpoints for recurrence-free survival when combined with Keytruda.

Sources

20minutos.es · 24matins.es · 324.cat · 4investors.de · 6yka.com · abcnews.al · abendblatt.de · actualidad.rt.com · ad-hoc-news.de · agenparl.eu · aimatmelanoma.org · aktiencheck.de · aktivni.si · albiladpress.com · albinfo.ch · aljazeera.com · altonivel.com.mx · alwakeelnews.com · amazon.nl · americafirstreport.com · americanbazaaronline.com · americanindependent.com · americanpress.com · anlatilaninotesi.com.tr · antiguatribune.com · apjii.or.id · apuntmedia.es · arabic.euronews.com · arabnews.pk · aripaev.ee · arstechnica.com · arynews.tv · athina984.gr · audi.com.au · augsburger-allgemeine.de · baocalitoday.com · barbadosgazette.com · barlamantoday.com · beteve.cat · bigodino.it · bio.uci.edu · biomedicalcue.it · bitcoinethereumnews.com · bitfinanzas.com · biznes.interia.pl · biznis.rs · block-builders.de · blocktempo.com

This summary has been updated 28 times: see revision history